ConductScience.org, home

Paper35628443

Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Feijóo-Bandín S and 10 others. Int J Mol Sci, 2022. Cited by 50 papers, by iCite.

Cite this record

ConductScience Library. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Papers, record 35628443. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35628443

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
50
iCite
Relative citation ratio, by iCite
4.23
iCite
Revised in PubMed
2022-07-16
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Feijóo-Bandín SSandrahttps://orcid.org/0000-0002-3739-5806
2Aragón-Herrera AAlana
3Otero-Santiago MManuel
4Anido-Varela LLaura
5Moraña-Fernández SSandra
6Tarazón EEstefaníahttps://orcid.org/0000-0003-3466-2558
7Roselló-Lletí EEsther
8Portolés MManuelhttps://orcid.org/0000-0002-4415-7160
9Gualillo OOrestehttps://orcid.org/0000-0002-7154-1328
10González-Juanatey JRJosé Ramón
11Lago FFrancisca

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Heart FailureMajor topic
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Animals
Glucose
Humans
Inflammation
Models, Animal
Sodium
Sodium-Glucose Transporter 2

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
PI21/01145Instituto de Salud Carlos IIIPubMed
Project number 734899European Regional Development Fund (FEDER) and European Union framework MSCA-RISE-H2020 ProgrammePubMed
GPC IN607B 2021 108Axencia Galega de InnovacionPubMed

Source PubMed

Download CSV of grants

References220

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132585073Role of NLRP3 inflammasome in liver disease.J Dig Dis2020https://conductscience.org/library/papers/32585073PubMed
233611885Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.Diabetes Metab J2021https://conductscience.org/library/papers/33611885PubMed
316307390Prevention of bone loss by phloridzin, an apple polyphenol, in ovariectomized rats under inflammation conditions.Calcif Tissue Int2005https://conductscience.org/library/papers/16307390PubMed
424848755Tofogliflozin: first global approval.Drugs2014https://conductscience.org/library/papers/24848755PubMed
515624123Phlorizin: a review.Diabetes Metab Res Rev2005https://conductscience.org/library/papers/15624123PubMed
628045402Inflammatory mechanisms linking obesity and metabolic disease.J Clin Invest2017https://conductscience.org/library/papers/28045402PubMed
73571496Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.J Clin Invest1987https://conductscience.org/library/papers/3571496PubMed
833760995Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy.Acta Diabetol2021https://conductscience.org/library/papers/33760995PubMed
933005037Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.Nat Rev Nephrol2021https://conductscience.org/library/papers/33005037PubMed
1034002329Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NFκB/AMPK/NLRP3 axis.Inflammopharmacology2021https://conductscience.org/library/papers/34002329PubMed
1131896553Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.Diabetes2020https://conductscience.org/library/papers/31896553PubMed
1220302302
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
J Med Chem2010https://conductscience.org/library/papers/20302302PubMed
1317167474Inflammation and metabolic disorders.Nature2006https://conductscience.org/library/papers/17167474PubMed
1423776070Phloretin and phlorizin promote lipolysis and inhibit inflammation in mouse 3T3-L1 cells and in macrophage-adipocyte co-cultures.Mol Nutr Food Res2013https://conductscience.org/library/papers/23776070PubMed
1517050778Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.J Pharmacol Exp Ther2007https://conductscience.org/library/papers/17050778PubMed
1616306358Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.Diabetes2005https://conductscience.org/library/papers/16306358PubMed
1729512713Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts.Mol Med Rep2018https://conductscience.org/library/papers/29512713PubMed
1833115828Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.Diabetes2021https://conductscience.org/library/papers/33115828PubMed
1910036327Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects.Biochim Biophys Acta1999https://conductscience.org/library/papers/10036327PubMed
2035418866Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1.Front Pharmacol2022https://conductscience.org/library/papers/35418866PubMed

See all 220 referencesDownload CSV of references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.

PMIDTitleJournalYearIn PapersSource
42236640Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study.Infect Dis Ther2026https://conductscience.org/library/papers/42236640PubMed
42232589Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study.Clin Kidney J2026https://conductscience.org/library/papers/42232589PubMed
42195246Uncoupling Erythropoiesis from Cardiorenal Effects: SGLT2 Inhibition in Non-Diabetic Heart Failure.Medicina (Kaunas)2026https://conductscience.org/library/papers/42195246PubMed
41899183SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge.J Clin Med2026https://conductscience.org/library/papers/41899183PubMed
41545323Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis.J Cell Mol Med2026https://conductscience.org/library/papers/41545323PubMed
41499173Dapagliflozin Reduces Kidney Inflammation in Alport Syndrome by Inhibiting the Stimulator of IFN Genes Pathway in Renal Tubular Epithelial Cells.Kidney3602026https://conductscience.org/library/papers/41499173PubMed
41466578Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases.Arthritis Rheumatol2026https://conductscience.org/library/papers/41466578PubMed
41011188Modulation of Macrophage Polarization by Traditional Chinese Medicine in HFpEF: A Review of Mechanisms and Therapeutic Potentials.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41011188PubMed
41010553Beyond the Cardio-Renal-Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins.J Clin Med2025https://conductscience.org/library/papers/41010553PubMed
40420176Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review.Cardiovasc Diabetol2025https://conductscience.org/library/papers/40420176PubMed
40193211Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies.J Am Soc Nephrol2025https://conductscience.org/library/papers/40193211PubMed
40182430Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes.Front Cardiovasc Med2025https://conductscience.org/library/papers/40182430PubMed
40149704Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation.Biomedicines2025https://conductscience.org/library/papers/40149704PubMed
40004134Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.Int J Mol Sci2025https://conductscience.org/library/papers/40004134PubMed
39639415Unveiling the podocyte-protective effect of sodium-glucose cotransporter-2 inhibitors.Kidney Res Clin Pract2025https://conductscience.org/library/papers/39639415PubMed
39254877The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/39254877PubMed
39211720A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects.Cureus2024https://conductscience.org/library/papers/39211720PubMed
39062954The Off-Target Cardioprotective Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors: An Overview.Int J Mol Sci2024https://conductscience.org/library/papers/39062954PubMed
38791409The Role of Inflammasomes in Heart Failure.Int J Mol Sci2024https://conductscience.org/library/papers/38791409PubMed
38675438View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38675438PubMed

See all 32 cited byDownload CSV of cited by

Genes15

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35628443

GET https://conductscience.org/api/papers/v1/35628443/references?page=2